OxlumoActive Ingredient(s): Lumasiran
FDA Approved: * November 23, 2020
Pharm Company: * ALNYLAM PHARMS INC
Category: Genetic Disorders
Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1). The most common side effects include injection site reactions and abdominal pain. Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) that reduces levels of glycolate oxidase (GO) enzyme by targeting the HAO1 messenger ribonucleic acid (mRNA) in hepatocytes through RNA interferenc... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Oxlumo 94.5 mg/.5ml Subcutaneous Injection, SolutionNDC: 71336-1002
Alnylam Pharmaceuticals, Inc.